RALEIGH, N.C., Aug. 17, 2011 (GLOBE NEWSWIRE) -- Timothy R. Wright, Chairman and Interim Chief Executive Officer of Curaxis Pharmaceutical Corporation (“Curaxis” or the “Company”) (OTCQB:CURX) (Frankfurt:8CX), announced today that the new management team and newly implemented board of directors have been working diligently through the transition phase and are moving forward in their evaluation of the Company’s current financial position, scientific collateral and strategic alternatives. On June 27, 2011, the Company announced changes to its Board of Directors (the “Board”) and its executive management team to better position the Company for its next phase of growth and development. The new Board has a wealth of experience and comprehensive knowledge of life sciences, operations and strategic management in the area of pharmaceuticals. In addition, the newly appointed Board members have significant experience in the necessary industry arenas to execute the Company’s business plan on an accelerated basis.
